Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ: VKTX )

29.75 +0.20 (+0.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
22 23 Next >
Viking Therapeutics Inc. (NASDAQ: VKTX) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
Weight Loss Drug Market Gets Crowded As Viking Therapeutics Drops Encouraging Phase 2 Data From Obesity Study
Viking Therapeutics' VK2735, a dual GLP-1 and GIP receptor agonist, achieved significant weight loss (up to 14.7%) in metabolic disorder patients. Safe, well-tolerated treatment with no observed... 
Via Benzinga
Nasdaq Rises 50 Points; Lowe's Earnings Top Views
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.07% to 39,043.13 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Viking Therapeutics (VKTX) Stock Up 96% Today?
Viking Therapeutics stock is up on Tuesday with heavy trading of VKTX shares after the company reported positive Phase 2 trial results! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
(VKTX) - Analyzing Viking Therapeutics's Short Interest
Via Benzinga
Recap: Viking Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results
Eli Lilly and Novo Nordisk fell modestly. 
Via Investor's Business Daily
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
Earnings Preview: Viking Therapeutics
Via Benzinga
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
Amazon, Progress Software And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by 1% on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. 
Via InvestorPlace
Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug
The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss. 
Via Investor's Business Daily
Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones gaining around 20 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. 
Via Benzinga
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns 
Via InvestorPlace
2 Rising Biotechs That Could Become the Next Novo Nordisk
Each of these companies has a big market in its sights. 
Via The Motley Fool
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune. 
Via InvestorPlace
2 Stocks That Could Soar This Year: Are They Buys?
They might perform well in 2024, but how will they do beyond that? 
Via The Motley Fool
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. 
Via MarketBeat
The 3 Best Biotech Stocks to Buy in January 2024
Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024
Lower interest rates and the low valuation of many biotech stocks are likely to result in many drug maker stocks being acquired in 2024. 
Via InvestorPlace
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint. 
Via The Motley Fool
Why Viking Therapeutics Was Crushing It This Week
Nowadays, it's good to be a developer of next-generation weight loss drugs. 
Via The Motley Fool
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.